State Street’s Inovio Pharmaceuticals INO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $516K | Buy |
296,310
+48,900
| +20% | +$80.5K | ﹤0.01% | 3652 |
|
|
2025
Q4 | $430K | Buy |
247,410
+61,200
| +33% | +$135K | ﹤0.01% | 3716 |
|
|
2025
Q3 | $436K | Buy |
186,210
+62,600
| +51% | +$120K | ﹤0.01% | 3692 |
|
|
2025
Q2 | $252K | Sell |
123,610
-390,538
| -76% | -$748K | ﹤0.01% | 3770 |
|
|
2025
Q1 | $838K | Buy |
514,148
+9,840
| +2% | +$19.7K | ﹤0.01% | 3468 |
|
|
2024
Q4 | $923K | Buy |
504,308
+13,646
| +3% | +$60.4K | ﹤0.01% | 3503 |
|
|
2024
Q3 | $2.84M | Buy |
490,662
+51,414
| +12% | +$424K | ﹤0.01% | 3199 |
|
|
2024
Q2 | $3.55M | Buy |
439,248
+350,567
| +395% | +$3.69M | ﹤0.01% | 3078 |
|
|
2024
Q1 | $1.23M | Buy |
88,681
+16,094
| +22% | +$139K | ﹤0.01% | 3415 |
|
|
2023
Q4 | $444K | Hold |
72,587
| – | – | ﹤0.01% | 3663 |
|
|
2023
Q3 | $339K | Sell |
72,587
-534
| -0.7% | -$2.95K | ﹤0.01% | 3774 |
|
|
2023
Q2 | $392K | Sell |
73,121
-2,252,911
| -97% | -$18.2M | ﹤0.01% | 3754 |
|
|
2023
Q1 | $22.9M | Sell |
2,326,032
-296,664
| -11% | -$5.06M | ﹤0.01% | 2131 |
|
|
2022
Q4 | $49.1M | Buy |
2,622,696
+453,865
| +21% | +$10.3M | ﹤0.01% | 1654 |
|
|
2022
Q3 | $44.9M | Sell |
2,168,831
-514,142
| -19% | -$13.2M | ﹤0.01% | 1660 |
|
|
2022
Q2 | $55.7M | Buy |
2,682,973
+743,979
| +38% | +$21M | ﹤0.01% | 1562 |
|
|
2022
Q1 | $83.5M | Buy |
1,938,994
+830,625
| +75% | +$37.4M | ﹤0.01% | 1421 |
|
|
2021
Q4 | $66.4M | Buy |
1,108,369
+196,097
| +21% | +$15.7M | ﹤0.01% | 1610 |
|
|
2021
Q3 | $78.4M | Buy |
912,272
+170,009
| +23% | +$17.1M | ﹤0.01% | 1460 |
|
|
2021
Q2 | $82.6M | Buy |
742,263
+54,302
| +8% | +$5.22M | ﹤0.01% | 1454 |
|
|
2021
Q1 | $76.6M | Sell |
687,961
-53,252
| -7% | -$7M | ﹤0.01% | 1437 |
|
|
2020
Q4 | $78.7M | Buy |
741,213
+74,428
| +11% | +$9.91M | ﹤0.01% | 1334 |
|
|
2020
Q3 | $92.8M | Buy |
666,785
+77,727
| +13% | +$16.2M | 0.01% | 1013 |
|
|
2020
Q2 | $191M | Buy |
589,058
+444,428
| +307% | +$71.4M | 0.01% | 671 |
|
|
2020
Q1 | $12.9M | Buy |
144,630
+12,535
| +9% | +$773K | ﹤0.01% | 2107 |
|
|
2019
Q4 | $5.23M | Sell |
132,095
-13,276
| -9% | -$400K | ﹤0.01% | 2827 |
|
|
2019
Q3 | $3.58M | Buy |
145,371
+583
| +0.4% | +$17.7K | ﹤0.01% | 2963 |
|
|
2019
Q2 | $5.11M | Sell |
144,788
-204,144
| -59% | -$8.11M | ﹤0.01% | 2809 |
|
|
2019
Q1 | $15.6M | Buy |
348,932
+68,219
| +24% | +$3.44M | ﹤0.01% | 2213 |
|
|
2018
Q4 | $13.5M | Buy |
280,713
+23,911
| +9% | +$1.45M | ﹤0.01% | 2258 |
|
|
2018
Q3 | $17.1M | Sell |
256,802
-69,891
| -21% | -$3.89M | ﹤0.01% | 2278 |
|
|
2018
Q2 | $15.4M | Sell |
326,693
-45,888
| -12% | -$2.53M | ﹤0.01% | 2313 |
|
|
2018
Q1 | $21.1M | Buy |
372,581
+38,581
| +12% | +$2.09M | ﹤0.01% | 2015 |
|
|
2017
Q4 | $16.6M | Buy |
334,000
+20,807
| +7% | +$1.29M | ﹤0.01% | 2174 |
|
|
2017
Q3 | $23.8M | Buy |
313,193
+132,524
| +73% | +$9.86M | ﹤0.01% | 1908 |
|
|
2017
Q2 | $17M | Sell |
180,669
-27,807
| -13% | -$2.38M | ﹤0.01% | 2109 |
|
|
2017
Q1 | $16.6M | Sell |
208,476
-3,780
| -2% | -$301K | ﹤0.01% | 2077 |
|
|
2016
Q4 | $17.7M | Sell |
212,256
-36,143
| -15% | -$3.27M | ﹤0.01% | 1987 |
|
|
2016
Q3 | $27.8M | Buy |
248,399
+39,558
| +19% | +$4.37M | ﹤0.01% | 1549 |
|
|
2016
Q2 | $23.2M | Buy |
208,841
+36,155
| +21% | +$4.39M | ﹤0.01% | 1655 |
|
|
2016
Q1 | $18M | Sell |
172,686
-30,996
| -15% | -$2.39M | ﹤0.01% | 1792 |
|
|
2015
Q4 | $16.4M | Sell |
203,682
-166,139
| -45% | -$13.2M | ﹤0.01% | 1860 |
|
|
2015
Q3 | $25.6M | Buy |
369,821
+35,982
| +11% | +$3.14M | ﹤0.01% | 1587 |
|
|
2015
Q2 | $32.7M | Sell |
333,839
-4,938
| -1% | -$528K | ﹤0.01% | 1528 |
|
|
2015
Q1 | $33.2M | Buy |
338,777
+96,315
| +40% | +$9.33M | ﹤0.01% | 1476 |
|
|
2014
Q4 | $26.7M | Buy |
242,462
+47,089
| +24% | +$5.75M | ﹤0.01% | 1591 |
|
|
2014
Q3 | $23.1M | Buy |
195,373
+4,117
| +2% | +$513K | ﹤0.01% | 1632 |
|
|
2014
Q2 | $24.8M | Buy |
191,256
+84,410
| +79% | +$9.96M | ﹤0.01% | 1663 |
|
|
2014
Q1 | $17.1M | Sell |
106,846
-49,327
| -32% | -$7.08M | ﹤0.01% | 1898 |
|
|
2013
Q4 | $21.7M | Buy |
156,173
+153,643
| +6,073% | +$15.4M | ﹤0.01% | 1690 |
|
|
2013
Q3 | $252K | Buy |
2,530
+1,448
| +134% | +$121K | ﹤0.01% | 3407 |
|
|
2013
Q2 | $42K | Buy |
+1,082
| New | +$32.8K | ﹤0.01% | 3462 |
|
Other funds holding INO
VCM
BCM
ACM
EP
State Street's INO Position: Q1 2026 in Review
State Street increased its Inovio Pharmaceuticals (INO) stake by 20% in Q1 2026, buying an estimated $80.5K and bringing the position to 296,310 shares worth $516K. The position accounts for ﹤0.01% of the portfolio, ranked #3652.
State Street first reported a position in INO in Q2 2013 and has held it in 52 quarters since. The position peaked at $191M in Q2 2020. 100 funds tracked by Wall St. Rank hold INO as of Q1 2026.
- State Street held 296,310 shares of Inovio Pharmaceuticals worth $516K as of Q1 2026.
- State Street bought 48,900 Inovio Pharmaceuticals shares in Q1 2026, an estimated $80.5K.
- Inovio Pharmaceuticals made up ﹤0.01% of State Street's portfolio in Q1 2026, its #3652 holding.
- State Street first reported a position in Inovio Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- State Street's Inovio Pharmaceuticals position peaked at $191M in Q2 2020.
- 100 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q1 2026.
Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.